Related Experiment Videos
[Cardiotoxicity of 5-fluorouracil]
Luis Teixeira1, Sonia Barry, Philippe Debourdeau
1Service de Médecine Interne et Oncologie Médicale, Hôpital Saint-Antoine, Paris, 184, rue du Faubourg Saint-Antoine, 75571 Paris Cedex 12.
Bulletin Du Cancer
|May 19, 2005
Summary
5-fluorouracil (5FU) chemotherapy can cause cardiotoxicity, presenting as chest pain or heart failure, though typically not life-threatening. Treatment involves stopping 5FU and supportive cardiac care, with most patients having a good prognosis.
Area of Science:
- Oncology
- Cardiology
- Pharmacology
Context:
- 5-fluorouracil (5FU) is a widely used antimetabolite chemotherapy agent.
- While known for toxicities like mucositis and leucopenia, 5FU-induced cardiotoxicity is less common but significant.
Purpose:
- To review the incidence, clinical presentation, pathophysiology, and management of 5-fluorouracil cardiotoxicity.
- To highlight the importance of recognizing and managing cardiac adverse events associated with 5FU treatment.
Summary:
- 5FU cardiotoxicity occurs in 1.5-18% of patients, with symptoms including chest pain, arrhythmias, myocardial infarction, and heart failure.
- Pathophysiology is debated, but myocardial toxicity is suggested; electrocardiographic findings are often nonspecific ischemic signs.
- Management involves discontinuing 5FU infusion and initiating symptomatic cardiologic treatment.
Impact:
- Understanding 5FU cardiotoxicity aids in early diagnosis and appropriate patient management.
- Despite a generally good prognosis, symptomatic cardiotoxicity carries a mortality risk of 2.2-13%.
- Further research is needed regarding secondary prophylaxis for 5FU-induced cardiotoxicity.